Clinical trialNCT03729596TerminatedPhase 1/PHASE2Interventional

MGC018 With or Without MGA012 in Advanced Solid Tumors

SponsorMacroGenicsEnrollment143Advanced Solid Tumor, AdultMelanomaMetastatic Castrate Resistant Prostate CancerNon Small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckTriple Negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors. Patients with solid tumors will be enrolled in the Dose Escalation Phase; Cohort Expansion will include metastatic castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), and melanoma. Patients who do not experience unacceptable toxicity or meet criteria for permanent discontinuation may undergo additional cycles for up to two years. Patients in Cohort Expansion will be followed for survival every 3 months for 2 years following last dose.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Ashley Ward, M.D.
MacroGenics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

St Vincent'S Health Network (kinghorn Cancer Centre)
Darlinghurst, Australia
Austin Health - Olivia Newton John Cancer Center
Heidelberg, Australia
Calvary Mater Newcastle
Waratah, Australia
the University of Queensland - Princess Alexandra Hospital (pah)
Woolloongabba, Australia

Poland

Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie Oddział Kliniczny Onkologii
Krakow, Poland
Med-Polonia Sp. Z O.O.
Poznan, Poland
Magodent Sp. Z O.O. Szpital Elbląska Oddział Onkologii Klinicznej/ Chemioterapii
Warsaw, Poland
Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy Oddział Badań Wczesnych Faz
Warsaw, Poland

Spain

Hospital Universitario Vall D'Hebron
Barcelona, Spain
Institut Català D'Oncologia - Hospital Universitari Germans Trias I Pujol
Barcelona, Spain
Hospital Ruber Internacional
Madrid, Spain
Hospital Universitario Hm Sanchinarro
Madrid, Spain

United States

Ucla Department of Medicine - Hematology/oncology
Santa Monica, California, United States
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
the Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland, United States
Start Midwest
Grand Rapids, Michigan, United States
Nebraska Methodist Hospital
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Carolina Biooncology Institute
Huntersville, North Carolina, United States
Inova Schar Cancer Institute
Fairfax, Virginia, United States
Virginia Cancer Specialist
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Vobramitamab duocarmazine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Nov 2018
Primary completion: 18 Mar 2023
Completion: 18 Mar 2023
Last update posted: 31 Jul 2025
Registered enrollment: 143
Registry id: NCT03729596

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.